ThermoGenesis Holdings, Inc

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ThermoGenesis Holdings, Inc. engages in the research, development, commercialization, and marketing of automated cell processing technologies for the cell and gene therapy field. It markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, CAR-Txpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company was founded by Philip H. Coelho in 1986 and is headquartered in Rancho Cordova, CA.

ThermoGenesis Holdings, Inc. (NASDAQ:THMO ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Paula Schwartz - Rx Communications Dr. Chris Xu - Chief Executive Officer Jeff Cauble - Chief Financial Officer Conference Call Participants Sean Lee - H.C. Wainwright Operator Good day, and welcome to the ThermoGenesis Holdings Conference Call and Webcast to Review Financial and Operating Results for the Third Quarter Ended September 30, 2022.

ThermoGenesis Holdings, Inc. (THMO) CEO Dr. Chris Xu on Q3 2022 Results - Earnings Call Transcript

ThermoGenesis Holdings, Inc. (THMO) delivered earnings and revenue surprises of -233.33% and 28.79%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ThermoGenesis Holdings, Inc. (THMO) Reports Q3 Loss, Misses Revenue Estimates

Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m.

ThermoGenesis Holdings Announces Financial Results for the Third Quarter Ended September 30, 2022 and Provides Corporate Update

Conference  Call to be Held on November 10, 2022 RANCHO CORDOVA, Calif. , Nov. 7, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that the Company will release its financial results for the third quarter ended September 30, 2022, and provide a corporate strategic update on Thursday, November 10, 2022.

ThermoGenesis Holdings to Announce Financial Results for the Third Quarter Ended September 30, 2022 and Provide a Corporate Strategic Update

RANCHO CORDOVA, Calif. , Oct. 28, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ: THMO) (the "Company"), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced the closing of its previously announced public offering of 11,783,572 shares of its common stock, $0.001 par value (the "Common Shares"), 2,892,858 pre-funded warrants to purchase Common Shares, and warrants to purchase up to an aggregate 14,676,430 Common Shares at an offering price to the public of $0.14 per share and associated warrant, for aggregate gross proceeds of approximately $2.05 million excluding the proceeds, if any, from the exercise of the warrants.

THERMOGENESIS CLOSES $2.05 MILLION PUBLIC OFFERING

RANCHO CORDOVA, Calif. , Oct. 25, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ: THMO) (the "Company"), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced the pricing of its public offering of 11,783,572 shares of its common stock, $0.001 par value (the "Common Shares") (or pre-funded warrants to purchase Common Shares in lieu thereof) and warrants to purchase up to an aggregate 11,783,572 Common Shares at an offering price to the public of $0.14 per share (or pre-funded warrant to purchase Common Shares in lieu thereof) and associated warrant.

THERMOGENESIS PRICES $2.05 MILLION PUBLIC OFFERING

RANCHO CORDOVA, Calif. , Sept. 7, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that Chris Xu, Ph.D.

ThermoGenesis Holdings to Present at the H.C. Wainwright 24th Annual Global Investment Conference

ThermoGenesis Holdings, Inc. (NASDAQ:THMO ) Q2 2022 Results Conference Call August 11, 2022 3:00 PM ET Company Participants Paula Schwartz - Rx Communications Dr. Chris Xu - Chief Executive Officer Jeff Cauble - Chief Financial Officer Conference Call Participants Sean Lee - H.C. Wainwright Operator Good day, and welcome to the ThermoGenesis Holdings Conference Call and Webcast to Review Financial and Operating Results for the Second Quarter Ended June 30, 2022.

ThermoGenesis Holdings, Inc. (THMO) CEO Dr. Chris Xu on Q2 2022 Results - Earnings Call Transcript

Driven by Sales of the AXP, Total Revenues for the Quarter Rose 38% Compared to Prior Year Conference Call to be Held Today at 12:00 p.m. PT/3:00 p.m.

ThermoGenesis Holdings Announces Financial Results for the Second Quarter Ended June 30, 2022 and Provides Corporate Update

Conference  Call to be Held on August 11, 2022 RANCHO CORDOVA, Calif. , Aug. 9, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the second quarter ended June 30, 2022 and provide a corporate strategic update on Thursday, August 11, 2022.

ThermoGenesis Holdings to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide a Corporate Strategic Update

Fathom Digital Manufacturing Co

Silverback Therapeutics

View

Penny stocks to watch right now The post Penny Stocks To Buy Now? 4 Stocks To Watch Before August Begins appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy Now? 4 Stocks To Watch Before August Begins

Kintara Therapeutics

BitNile Holdings

There are over 500 Nasdaq & NYSE listed stocks, right, and warrants… The post 3 Red Hot Penny Stocks Under $1 To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Red Hot Penny Stocks Under $1 To Watch Before Next Week

ThermoGenesis Holdings, Inc. (NASDAQ:THMO ) Q1 2022 Earnings Conference Call May 19, 2022 4:30 AM ET Company Participants Paula Schwartz - Rx Communications Chris Xu - Chief Executive Officer Jeff Cauble - Chief Financial Officer Conference Call Participants Operator Good day, and welcome to the ThermoGenesis Holdings Conference Call and Webcast to review Financial and Operating Results for the First Quarter Ended March 31st, 2012. As a reminder, all participants will be in listen-only mode.

ThermoGenesis Holdings, Inc. (THMO) CEO Chris Xu on Q1 2022 Results - Earnings Call Transcript

ThermoGenesis Holdings Announces Financial Results for the First Quarter Ended March 31, 2022 and Provides Corporate Update

Conference  Call to be Held on May 19, 2022 RANCHO CORDOVA, Calif. , May 18, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the first quarter ended March 31, 2022 and provide a corporate strategic update on Thursday, May 19, 2022, after the close of trading.

ThermoGenesis Holdings to Announce Financial Results for the First Quarter Ended March 31, 2022 and Provide a Corporate Strategic Update

Thermogenesis Holdings, Inc. (THMO) CEO Chris Xu on Q4 2021 Results - Earnings Call Transcript

Company Signs License Agreement With Boyalife Genomics and will Form TG Biosynthesis Division to Operate as CDMO for Cell and Cell-Based Gene Therapies Leases 35,475 SF To Be Built-Out as cGMP Compliant Facility in Sacramento Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m.

ThermoGenesis Holdings Announces Year End 2021 Financial Results and Provides Corporate Update

Conference  Call to be Held on March 28, 2022 RANCHO CORDOVA, Calif. , March 23, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the fourth quarter ended December 31, 2021 and provide a corporate strategic update on Monday, March 28, 2022, after the close of trading.

ThermoGenesis Holdings to Announce Financial Results for the Fourth Quarter Ended December 31, 2021 and Provide a Corporate Strategic Update

RANCHO CORDOVA, Calif., Jan. 11, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), today announced that the Company's 2021 Annual Meeting of Stockholders (the "Annual Meeting") will reconvene on Thursday, January 13, 2022 at 12:00 p.m.

ThermoGenesis Holdings to Hold Reconvened Annual Meeting of Stockholders on January 13, 2022

RANCHO CORDOVA, Calif., Jan. 10, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that Chief Financial Officer, Jeff Cauble, will present a company overview at the H.C.

ThermoGenesis Holdings to Present at the H.C. Wainwright BioConnect Virtual Conference

RANCHO CORDOVA, Calif., Dec. 17, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), announced that the Company's Annual Meeting of Stockholders (the "Annual Meeting") scheduled for Thursday, December 16, 2021 at 9:00 a.m.

ThermoGenesis Holdings Announces Adjournment of Annual Meeting of Stockholders

ThermoGenesis Holdings (NASDAQ:THMO) reported its Q3 earnings results on Friday, November 12, 2021 at 04:00 PM. Here's what investors need to know about the announcement.

Recap: ThermoGenesis Holdings Q3 Earnings

Thermogenesis Holdings, Inc. (THMO) CEO Jeffery Cauble on Q3 2021 Results - Earnings Call Transcript

RANCHO CORDOVA, Calif., Nov. 12, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the third quarter ended September 30, 2021 and provided a corporate strategic update.

ThermoGenesis Holdings Announces Financial Results for the Third Quarter Ended September 30, 2021, and Provides Corporate Update

RANCHO CORDOVA, Calif., Nov. 5, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the third quarter ended September 30, 2021 and provide a corporate strategic update on Friday, November 12, 2021, after the close of trading.

News for ThermoGenesis Holdings, Inc Stock (THMO)